Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
Ad hoc announcement pursuant to Art. 53 LR Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous Clascoterone treatment continued to gain hair through Month 12. In contrast, patients who switched to the placebo from Month 7 onwards experienced a reduction in treatment gains, demonstrating the importance of ongoing therapy. NDA a
Soins de santé et hôpitaux, Santé
2026-04-15 1:07 AM EDT | Cosmo Pharmaceuticals N.V.
Jones Healthcare Group's Near-Term Emissions Reduction Targets Validated by the Science Based Targets Initiative
London, Ontario--(Newsfile Corp. - April 14, 2026) - Jones Healthcare Group's near-term greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi), marking a significant step in the company's commitment to reducing emissions across its operations and broader value chain. As part of its validated targets, Jones commits to reduce absolute scope 1 and scope 2 greenhouse gas emissions 43.26% by 2030 from a 2023 base year. The company also c
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-14 10:00 AM EDT | Jones Healthcare Group
Cheelcare to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference
Markham, Ontario--(Newsfile Corp. - April 14, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, announced today that it will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference take place April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, Canada. Cheelcare's CEO, Eugene Cherny and VP of Growth, Allan Boyd will present and participate in one-on-one meetings wit
Technologies, Biotechnologies, Services bancaires d’investissement, Santé
2026-04-14 7:30 AM EDT | Bloom Burton & Co. Inc.
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with
Biotechnologies, Cannabis, Santé, Producteurs de cannabis
2026-04-14 7:27 AM EDT | Cardiol Therapeutics Inc.
Dr. Paula Muto, Founder of UberDoc, Appointed to U.S. Federal Health Advisory Committee
Boston, Massachusetts--(Newsfile Corp. - April 14, 2026) - UberDoc Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) ("UberDoc" or the "Company"), an innovative healthcare platform empowering patients to connect with top physicians directly at transparent, upfront prices, today announced that its Founder, Dr. Paula Muto, has been appointed to the National Committee on Vital and Health Statistics (NCVHS), a federal advisory body to U.S. Department of Health and Human Services (HHS) and Centers
2026-04-14 1:00 AM EDT | UberDoc
Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets
Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities. The upgrade pro
2026-04-13 9:51 AM EDT | Rapid Dose Therapeutics Corp.
Fotonara and PhantomOmics Announce Revolutionary Partnership and "Good for All Humans" Initiative to Transform Affordable Housing into Sovereign Health Guardians
Calgary, Alberta--(Newsfile Corp. - April 13, 2026) - Fotonara Inc., a pioneer in advanced manufacturing and sovereign smart building infrastructure, and PhantomOmics Inc., a visionary in proactive health technology, today announced a landmark global commercialization partnership. Together, the two Calgary-based tech innovators are launching the "Good for All Humans" initiative—a sweeping joint mission to make high-fidelity, preventative health monitoring a standard, low-cost uti
Technologies, Soins de santé et hôpitaux, Capteurs, Santé
2026-04-13 8:15 AM EDT | PhantomOmics Inc.
CURED Nutrition Joins One Hemp, Strengthening Industry Alignment Ahead of Key Federal Legislative Deadline
Washington, D.C.--(Newsfile Corp. - April 13, 2026) - CURED Nutrition, a Colorado-based wellness brand formulating non-intoxicating, full-spectrum cannabinoid supplements, today announced it has joined ONE HEMP, a national industry coalition advancing quality standards, transparency, and responsible federal regulation across the hemp CBD marketplace. The announcement comes as the industry approache
2026-04-13 7:55 AM EDT | OneHemp
ProMIS Neurosciences Invited to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
Cambridge, Massachusetts--(Newsfile Corp. - April 13, 2026) - ProMIS Neurosciences, Inc. (NASDAQ: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer, will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference. The conference is being held April 21-22, 2026, at the Metro Toronto Convention Centre in Toronto, O
Technologies, Biotechnologies, Services bancaires d’investissement, Santé
2026-04-13 7:30 AM EDT | Bloom Burton & Co. Inc.
WELL Health and WELLSTAR to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, British Columbia--(Newsfile Corp. - April 13, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, and its majority-owned
Technologies, Biotechnologies, Services bancaires d’investissement, Santé
2026-04-13 7:30 AM EDT | Bloom Burton & Co. Inc.
Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - April 13, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using it
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-04-13 7:00 AM EDT | Phio Pharmaceuticals Corp.
HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
Toronto, Ontario--(Newsfile Corp. - April 13, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce that the Company will be participating as a presenting company at the 2026 Bloom Burton & Co. Healthcar
Technologies, Biotechnologies, Services bancaires d’investissement, Santé
2026-04-13 7:00 AM EDT | Bloom Burton & Co. Inc.
UberDoc Health Technologies Corp. Announces Upcoming Investor Webinar
Boston, Massachusetts--(Newsfile Corp. - April 13, 2026) - UberDoc Health Technologies Corp. (CSE: APPT) (FSE: 4KL0) ("UberDoc" or the "Company") is pleased to announce that Sean Kearney, Chief Executive Officer, and Dr. Paula Muto, Founder and Chief Medical Advisor, will present an introduction to UberDoc in a live investor webinar taking place on Wednesday, April 15, 2026, at 11:00 AM PT / 2:00 PM ET.
2026-04-13 1:00 AM EDT | UberDoc
Voting Results of Cosmo's 2026 AGM
Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced that its shareholders approved all voting items at today’s Ordinary Annual General Meeting (AGM). A total of 10,354,065 ordinary shares of the share capital of Cosmo were represented at this general meeting of shareholders. These shares make up 59.02% of the total outstanding ordinary shares in the share capital of Cosmo as of the record
Soins de santé et hôpitaux, Santé
2026-04-10 9:16 AM EDT | Cosmo Pharmaceuticals N.V.
Safe Supply Streaming Co Ltd. Reports Results of Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company") reports that its Annual General and Special Meeting of Shareholders (the "Meeting") was held on April 8, 2026 in Toronto, Ontario. The following is a summary of the voting results for each matter put before shareholders at the Meeting. Meeting Results The following resolutions were voted on and approv
2026-04-10 7:03 AM EDT | Altrova Health Inc.
AtomVie Global Radiopharma to Present at The Bloom Burton & Co. Healthcare Investor Conference 2026
Hamilton, Ontario--(Newsfile Corp. - April 9, 2026) - AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in GMP manufacturing for clinical and commercial supply of radiopharmaceuticals and their worldwide distribution, is pleased to announce that they will be presenting at the Bloom Burton & Co. Healthcare Investor Conference (BBHIC) 2026, taking place at the Metro Convention Centre in Toronto,
Technologies, Biotechnologies, Services bancaires d’investissement, Santé
2026-04-09 10:00 AM EDT | Bloom Burton & Co. Inc.
Akanda Corp. Announces Reverse Stock Split
Toronto, Ontario--(Newsfile Corp. - April 9, 2026) - Akanda Corp. (NASDAQ: AKAN) (the "Company" or "Akanda"), today announced that it expects to implement a 1-for-4.5 reverse stock split of the Company's common shares effective April 13, 2026. The reverse stock split was previously approved by the Company's shareholders on November 28, 2025 and Board of Directors on March 23, 2026 and will begin trading on an adjusted basis giving effect to the reverse stock split at the opening of market on
Cannabis, Santé, Cultivateurs de cannabis, Producteurs de cannabis
2026-04-09 8:30 AM EDT | Akanda Corp
FloraWorks Announces TruCBN(TM) Readiness for the CMS Substance Access BEI Program with Full Clinical and Safety Substantiation
Portland, Oregon--(Newsfile Corp. - April 9, 2026) - FloraWorks today announced that TruCBN™ 50 mg softgels are available to healthcare organizations evaluating sleep-focused hemp products for the CMS Substance Access Beneficiary Engagement Incentive (BEI) program. In a published 1,020-person randomized, double-blind, placebo-controlled clinical trial, TruCBN™ 50 mg dose demonstrated statistically significant improvement in sleep quality. Real-world evidence has
Technologies, Cannabis, Santé, Producteurs de cannabis
2026-04-09 8:00 AM EDT | FloraWorks
Cheelcare Delivers First Curio Robotic Complex-Rehab Power Wheelchair to Paying Customers and Achieves Record Companion Sales
Markham, Ontario--(Newsfile Corp. - April 9, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced the delivery of its first Curio robotic complex-rehab power wheelchair to paying customers, marking the Company's transition into commercial production and initial revenue generation for its flagship power wheelchair platform. This milestone is complemented by record Companion unit sales in Marc
2026-04-09 7:30 AM EDT | Cheelcare Inc.
Promino Nutritional Sciences Launches NCAA Division I Athlete Platform Through Multi-Sport NIL Partnership with Virginia Military Institute
Burlington, Ontario--(Newsfile Corp. - April 9, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTC: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a developer of advanced proprietary amino acid formulations for muscle health, today announced a multi-sport Name, Image and Likeness ("NIL") partnership with eight NCAA Division I student-athletes at the Virginia Military Institute ("VMI"). This agreement marks the formal launch of the Promino NCAA Athlete Platform, a strategic ini
Aliments / boissons, Sports, Santé
2026-04-09 7:00 AM EDT | Promino Nutritional Sciences, Inc.